Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shozo Senba"'
Autor:
Takeshi Siraishi, Kyohei Yamaguchi, Shozo Senba, Ikuko Yamaguchi, Michiyasu Murakami, Hiroki Hashimoto
Publikováno v:
Supportive Care in Cancer. 22:905-909
Patients with gastrointestinal cancer who were receiving moderately emetogenic chemotherapy (MEC) were switched from granisetron, a first-generation 5-hydroxytryptamine-3 receptor antagonist, to palonosetron at our hospital. In the present study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a55589aba0e06ca39e0865b714ed3765
https://doi.org/10.1007/s00520-013-2046-6
https://doi.org/10.1007/s00520-013-2046-6
Autor:
Hiroki, Hashimoto, Michiyasu, Murakami, Kyoko, Shinozaki, Ryota, Nakanishi, Hidetoshi, Kawaguchi, Takashi, Nishizaki, Shozo, Senba
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 42(7)
Drug cost is considered an important factor in treatment compliance for cancer patients. However, it is difficult to calculate individual drug costs. We were previously unable to provide sufficient information on costs to cancer patients starting dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::58ddb6a612daeebf788409e58f4df75a
https://pubmed.ncbi.nlm.nih.gov/26197746
https://pubmed.ncbi.nlm.nih.gov/26197746
Autor:
Tsuyoshi, Muta, Hideyuki, Nakanishi, Megumi, Yasunaga, Shozo, Senba, Hiromichi, Murakami, Shin, Kan, Yoko, Ueda, Tomoaki, Fujisaki
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 38(2)
Recently, the safety and effectiveness of bortezomib for patients with multiple myeloma and renal failure has been reported. In this study, we retrospectively analyzed the 8 myeloma patients with renal failure who have received bortezomib in our hosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3c7d3d2cc303ec29516e2dd852c1ca4a
https://pubmed.ncbi.nlm.nih.gov/21368487
https://pubmed.ncbi.nlm.nih.gov/21368487
Autor:
Shozo Senba, Kyoko Shinozaki, Michiyasu Murakami, Takashi Nishizaki, Hidetoshi Kawaguchi, Ryota Nakanishi, Hiroki Hashimoto
Publikováno v:
Journal of Clinical Oncology. 33:e17797-e17797
e17797 Background: Drug cost is considered an important factor in the continuation of treatment for cancer patients. However, it is difficult to calculate individual drug cost. We were not able to ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::466f552f564366c7bd4f7b2097b0a66a
https://doi.org/10.1200/jco.2015.33.15_suppl.e17797
https://doi.org/10.1200/jco.2015.33.15_suppl.e17797